Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. (Q46675575)

24 December 2017

title

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. (English)

1 reference

24 December 2017

0 references

1 reference

15

David A Reardon

1 reference

24 December 2017

6

Timothy Cloughesy

1 reference

24 December 2017

author name string

Antonio Omuro

1

1 reference

24 December 2017

Gordana Vlahovic

2

1 reference

24 December 2017

Michael Lim

3

1 reference

24 December 2017

Solmaz Sahebjam

4

1 reference

24 December 2017

Joachim Baehring

5

1 reference

24 December 2017

Alfredo Voloschin

7

1 reference

24 December 2017

Shakti H Ramkissoon

8

1 reference

24 December 2017

Keith L Ligon

9

1 reference

24 December 2017

Robert Latek

10

1 reference

24 December 2017

Ricardo Zwirtes

11

1 reference

24 December 2017

Lewis Strauss

12

1 reference

24 December 2017

Prashni Paliwal

13

1 reference

24 December 2017

Christopher T Harbison

14

1 reference

24 December 2017

John H Sampsonc

16

1 reference

24 December 2017

publication date

28 October 2017

1 reference

24 December 2017

published in

Neuro-Oncology

1 reference

24 December 2017

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Prospects of immune checkpoint modulators in the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

A comprehensive profile of recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Immunotherapy advances for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

PD-L1 expression and prognostic impact in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Bevacizumab and daily temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOX208

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892140

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

3 November 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892140

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

3 November 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5892140

3 November 2018

Identifiers

DOI

10.1093/NEUONC/NOX208

1 reference

24 December 2017

PMC publication ID

5892140

0 references

1 reference

24 December 2017